A carregar...
Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections
PURPOSE: Since the launch of belimumab in 2011, the BLyS antibody has been increasingly used in the therapy of systemic Lupus erythematosus (SLE). Comparative studies showed that the intravenous (i.v.) and subcutaneous (s.c.) administration forms do not differ in their efficacy. Since the approval o...
Na minha lista:
| Publicado no: | Patient Prefer Adherence |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839583/ https://ncbi.nlm.nih.gov/pubmed/31806937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S227208 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|